As Head of the U.S. Plasma Derived Therapies Business Unit at Takeda, Brandon is responsible for ensuring that the company’s critical, life-saving plasma derived medicines are available for the thousands of people with rare and complex diseases who rely on them. In his role, he oversees the business performance, marketing and strategy for the business unit’s multiple brands while leading and coaching his team. Brandon was previously the Head of the U.S. Immunology/Albumin Franchise at Takeda before assuming his current position. Prior to Takeda’s acquisition of Shire in January 2019, Brandon served as Vice President of Sales for U.S. Immunology and later as Vice President of U.S. Immunology Institutional Sales & Marketing at Shire. During this time, he played an integral role leading the sales and marketing teams through organizational, market and leadership changes, while navigating a complex supply shortage environment. Prior to his experience with Shire and Takeda, Brandon held a number of positions with some of the leading pharmaceutical companies, including Baxalta, Baxter, and Eli Lilly and Company. He holds a BA in Business Administration from Hanover College and an MBA from the Massachusetts Institute of Technology Sloan School of Management.